HC Wainwright Analysts Increase Earnings Estimates for FHTX

Foghorn Therapeutics Inc. (NASDAQ:FHTX – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 earnings per share estimates for Foghorn Therapeutics in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of $0.09 for the year, up from their previous estimate of ($0.91). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($0.07) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.39) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($1.46) EPS, FY2029 earnings at ($1.44) EPS and FY2030 earnings at ($1.43) EPS.

Other research analysts have also issued research reports about the company. TD Cowen lowered Foghorn Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 1st. BTIG Research downgraded shares of Foghorn Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 1st. Guggenheim lowered their target price on shares of Foghorn Therapeutics from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, October 2nd. Evercore lowered shares of Foghorn Therapeutics from an “outperform” rating to an “in-line” rating and set a $3.00 target price for the company. in a research report on Tuesday, October 13th. Finally, Citigroup cut shares of Foghorn Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Thursday, October 1st. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.14.

View Our Latest Stock Analysis on FHTX

Foghorn Therapeutics Stock Up 1.0%

NASDAQ:FHTX opened at $2.07 on Thursday. The stock has a market cap of $124.12 million, a P/E ratio of 29.58 and a beta of 3.22. The business’s 50-day moving average price is $2.79 and its two-hundred day moving average price is $4.52. Foghorn Therapeutics has a twelve month low of $1.79 and a twelve month high of $7.61.

Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of ($0.24) by $1.04. Foghorn Therapeutics had a negative return on equity of 13.46% and a net margin of 8.40%. The business had revenue of $83.54 million during the quarter, compared to analysts’ expectations of $7.10 million.

Institutional Investors Weigh In On Foghorn Therapeutics

A number of institutional investors have recently made changes to their positions in FHTX. BlackRock Inc. purchased a new position in Foghorn Therapeutics in the 2nd quarter worth $12,819,000. Renaissance Technologies LLC lifted its stake in Foghorn Therapeutics by 36.5% in the first quarter. Renaissance Technologies LLC now owns 406,425 shares of the company’s stock worth $1,943,000 after purchasing an additional 108,689 shares during the last quarter. Candriam S.C.A. bought a new stake in Foghorn Therapeutics in the first quarter worth $1,500,000. Squarepoint Ops LLC boosted its position in Foghorn Therapeutics by 25.6% during the second quarter. Squarepoint Ops LLC now owns 130,346 shares of the company’s stock valued at $636,000 after buying an additional 26,603 shares during the period. Finally, SCS Capital Management LLC purchased a new stake in Foghorn Therapeutics during the second quarter valued at about $522,000. Hedge funds and other institutional investors own 61.55% of the company’s stock.

Top Foghorn Therapeutics Stories

Investors following FHTX have been watching these stories:

  • Positive Sentiment: HC Wainwright also kept its Buy rating and $5 price target. It raised its FY2026 EPS estimate to $0.09 from a previous loss forecast of $0.91 per share, an improvement that could support sentiment. HC Wainwright analyst estimates
  • Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Foghorn investors. The notice does not establish wrongdoing, but the investigation may add legal uncertainty. Pomerantz investor alert
  • Negative Sentiment: HC Wainwright cut its Q4 2026 EPS forecast and substantially lowered estimates for FY2027–FY2030, now projecting annual losses in those years. The revisions point to a weaker longer-term earnings outlook despite the firm’s Buy rating. HC Wainwright analyst estimates

About Foghorn Therapeutics

(Get Free Report)

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.

Recommended Stories

Earnings History and Estimates for Foghorn Therapeutics (NASDAQ:FHTX)

Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.